Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9051 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.9051 |
High Similarity |
NPD1613 |
Approved |
0.8897 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8832 |
High Similarity |
NPD3027 |
Phase 3 |
0.8824 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8633 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8551 |
High Similarity |
NPD2861 |
Phase 2 |
0.8489 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8382 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8312 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8247 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8169 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8165 |
Intermediate Similarity |
NPD5494 |
Approved |
0.8105 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8101 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8077 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7986 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7956 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7933 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7933 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7927 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7898 |
Intermediate Similarity |
NPD37 |
Approved |
0.7877 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7866 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7862 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7862 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7862 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7862 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7862 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7853 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7853 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7853 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7778 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7758 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7755 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7755 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7721 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7683 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7665 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7622 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7622 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7613 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7609 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7605 |
Intermediate Similarity |
NPD7054 |
Approved |
0.76 |
Intermediate Similarity |
NPD4536 |
Approved |
0.76 |
Intermediate Similarity |
NPD4538 |
Approved |
0.76 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7574 |
Intermediate Similarity |
NPD228 |
Approved |
0.7569 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7569 |
Intermediate Similarity |
NPD8651 |
Approved |
0.756 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7552 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7548 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7547 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7532 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7529 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD1512 |
Approved |
0.75 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7483 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7471 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7469 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7469 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7466 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7457 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7452 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7451 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7426 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7426 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7425 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7425 |
Intermediate Similarity |
NPD27 |
Approved |
0.7414 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7412 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.741 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7407 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7399 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7389 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7386 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7386 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7384 |
Intermediate Similarity |
NPD4577 |
Approved |
0.7384 |
Intermediate Similarity |
NPD4578 |
Approved |
0.7384 |
Intermediate Similarity |
NPD7313 |
Approved |
0.7384 |
Intermediate Similarity |
NPD7310 |
Approved |
0.7384 |
Intermediate Similarity |
NPD7312 |
Approved |
0.7384 |
Intermediate Similarity |
NPD7311 |
Approved |
0.7383 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7379 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7375 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7368 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7365 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7365 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7362 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7355 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7355 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7351 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7351 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7342 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7341 |
Intermediate Similarity |
NPD7309 |
Approved |
0.7338 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7338 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7338 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7338 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7326 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.732 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7308 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7308 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7305 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7301 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7301 |
Intermediate Similarity |
NPD5929 |
Approved |
0.729 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.729 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7246 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7241 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7241 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7241 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7234 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7233 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7226 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7226 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7219 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7206 |
Intermediate Similarity |
NPD968 |
Approved |
0.7197 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7193 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD7340 |
Approved |
0.717 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7161 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.716 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD290 |
Approved |
0.7153 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7152 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7152 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7152 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7152 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7134 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7134 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7134 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7134 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7125 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7115 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7115 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7115 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7114 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7108 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7107 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7103 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7101 |
Intermediate Similarity |
NPD6071 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7092 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7091 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7089 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7089 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7086 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7078 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7073 |
Intermediate Similarity |
NPD6072 |
Discontinued |
0.7073 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7063 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7059
|
Intermediate Similarity |
NPD2238 |
Phase 2 |